{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:50:21Z","timestamp":1760550621921,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":1041,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.4103\/ijmm.ijmm_18_90","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T10:25:27Z","timestamp":1533551127000},"page":"224-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors"],"prefix":"10.1016","volume":"36","author":[{"given":"Farhad","family":"Zamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Ajdarkosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh","family":"Safarnezhad-Tameshkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Azarkeivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"Naserifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshid","family":"Vafaeimanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4103\/ijmm.IJMM_18_90_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12879-017-2765-2","article-title":"WHO guidelines on testing for hepatitis B and C \u2013 Meeting targets for testing","volume":"17","author":"Hellard","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.4103\/ijmm.IJMM_18_90_bib2","doi-asserted-by":"crossref","first-page":"e62030","DOI":"10.5812\/hepatmon.62030","article-title":"Distribution of hepatitis C virus genotypes in Rasht, capital city of Guilan province, Northern part of Iran","volume":"18","author":"Naghipour-Khalkhaliani","year":"2018","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2008-7802.164832","article-title":"Trend in prevalence of hepatitis C virus infection among \u03b2-thalassemia major patients: 10 years of experience in Iran","volume":"6","author":"Jafroodi","year":"2015","journal-title":"Int J Prev Med"},{"key":"10.4103\/ijmm.IJMM_18_90_bib4","first-page":"45","article-title":"Frequency of thalassemia in Iran and Khorasan Razavi","volume":"1","author":"Khodaei","year":"2013","journal-title":"Int J Pediatr"},{"key":"10.4103\/ijmm.IJMM_18_90_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12288-011-0057-3","article-title":"Blood transfusion transmitted infections in multiple blood transfused patients of beta thalassaemia","volume":"27","author":"Vidja","year":"2011","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.4103\/ijmm.IJMM_18_90_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5812\/hepatmon.852","article-title":"Transfusion transmitted hepatitis: Where do we stand now? A one center study in upper Egypt","volume":"12","author":"El-Faramawy","year":"2012","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.micpath.2017.06.045","article-title":"Hepatitis E virus seroprevalence rate among eastern mediterranean and Middle Eastern countries; A systematic review and pooled analysis","volume":"110","author":"Karbalaie Niya","year":"2017","journal-title":"Microb Pathog"},{"key":"10.4103\/ijmm.IJMM_18_90_bib8","first-page":"S118","article-title":"Prevalence of anti HCV infection in patients with beta-thalassemia in Isfahan-Iran","volume":"3","author":"Ataei","year":"2012","journal-title":"Int J Prev Med"},{"key":"10.4103\/ijmm.IJMM_18_90_bib9","first-page":"216","article-title":"Polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 Patients treated by pegylated interferon and ribavirin","volume":"11","author":"Safarnezhad Tameshkel","year":"2016","journal-title":"Iran J Pathol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib10","doi-asserted-by":"crossref","first-page":"9032627","DOI":"10.1155\/2016\/9032627","article-title":"Seroprevalence of hepatitis C, hepatitis B, cytomegalovirus, and human immunodeficiency viruses in multitransfused thalassemic children in upper Egypt","volume":"2016","author":"Mahmoud","year":"2016","journal-title":"Adv Hematol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib11","first-page":"319","article-title":"Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in iran: A multicenter study","volume":"9","author":"Mirmomen","year":"2006","journal-title":"Arch Iran Med"},{"key":"10.4103\/ijmm.IJMM_18_90_bib12","doi-asserted-by":"crossref","first-page":"e37089","DOI":"10.5812\/hepatmon.37089","article-title":"Next steps toward eradication of hepatitis C in the era of direct acting antivirals","volume":"16","author":"Hesamizadeh","year":"2016","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.micpath.2017.01.060","article-title":"Prevalence of resistant associated variants (RAVs) in the na\u00efve HCV patient candidate for direct acting antiviral (DAA) therapy","volume":"105","author":"Karbalaie Niya","year":"2017","journal-title":"Microb Pathog"},{"key":"10.4103\/ijmm.IJMM_18_90_bib14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.4103\/ijmm.IJMM_18_90_bib15","doi-asserted-by":"crossref","first-page":"e23564","DOI":"10.5812\/hepatmon.23564","article-title":"Efficacy of prolonged treatment with pegylated interferon (Peg-IFN) and ribavirin in thalassemic patients with hepatitis C who relapsed after previous peg-IFN-based therapy","volume":"15","author":"Sandoughdaran","year":"2015","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.29139","article-title":"Elbasvir\/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: A phase III study","volume":"66","author":"H\u00e9zode","year":"2017","journal-title":"Hepatology"},{"key":"10.4103\/ijmm.IJMM_18_90_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"Electronic address: easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/ijmm.IJMM_18_90_bib19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4103\/ijmm.IJMM_18_90_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/TCRM.S134818","article-title":"Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials","volume":"13","author":"Yang","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.4103\/ijmm.IJMM_18_90_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5812\/hepatmon.6592","article-title":"Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy","volume":"12","author":"Tabatabaei","year":"2012","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib22","first-page":"926","article-title":"Treatment of chronic hepatitis C in thalassemia major patients","volume":"67","author":"Sajjad","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"10.4103\/ijmm.IJMM_18_90_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/apt.14197","article-title":"Randomised clinical trial: Sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection","volume":"46","author":"Mangia","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.4103\/ijmm.IJMM_18_90_bib24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.4103\/ijmm.IJMM_18_90_bib25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.4103\/ijmm.IJMM_18_90_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jceh.2017.08.002","article-title":"Generic direct acting antivirals in treatment of chronic hepatitis C infection in patients of thalassemia major","volume":"7","author":"Nagral","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/ajh.24911","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies","volume":"92","author":"Origa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1572-0241.2004.04049.x","article-title":"Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection","volume":"99","author":"Metwally","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2002.05390.x","article-title":"Iron as a comorbid factor in chronic viral hepatitis","volume":"97","author":"Bonkovsky","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.4103\/ijmm.IJMM_18_90_bib30","first-page":"e13136","article-title":"Serum iron markers in patients with chronic hepatitis C infection","volume":"13","author":"Vagu","year":"2013","journal-title":"Hepat Mon"},{"key":"10.4103\/ijmm.IJMM_18_90_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/00365548.2012.677545","article-title":"Serum ferritin levels in chronic hepatitis C patients during antiviral therapy and prediction of treatment response","volume":"44","author":"Barut","year":"2012","journal-title":"Scand J Infect Dis"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720304904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720304904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:16:27Z","timestamp":1759346187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085720304904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0255085720304904"],"URL":"https:\/\/doi.org\/10.4103\/ijmm.ijmm_18_90","relation":{},"ISSN":["0255-0857"],"issn-type":[{"type":"print","value":"0255-0857"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/ijmm.IJMM_18_90","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Indian Journal of Medical Microbiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}